{"id":32171,"date":"2025-04-22T13:54:48","date_gmt":"2025-04-22T05:54:48","guid":{"rendered":"https:\/\/flcube.com\/?p=32171"},"modified":"2025-04-22T13:54:49","modified_gmt":"2025-04-22T05:54:49","slug":"rona-therapeutics-wins-nmpa-ind-approval-for-sirna-hypertension-drug-rn1871","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32171","title":{"rendered":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871"},"content":{"rendered":"\n<p>Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China&#8217;s National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.<\/p>\n\n\n\n<p><strong>Mechanism of Action<\/strong><br>RN1871 is engineered to silence AGT mRNA expression in the liver, thereby inhibiting the production of a key precursor protein in the Renin-Angiotensin-Aldosterone System (RAAS). By targeting this critical pathway in blood pressure regulation, RN1871 aims to provide long-lasting blood pressure control. Preclinical studies have demonstrated its potential to offer a novel therapeutic option for the over 1.5 billion people affected by hypertension globally.<\/p>\n\n\n\n<p><strong>Clinical Development and Future Outlook<\/strong><br>With IND approval secured, Rona Therapeutics is set to initiate clinical trials to evaluate the safety and efficacy of RN1871 in patients with hypertension. This development highlights the company&#8217;s commitment to leveraging siRNA technology to address significant unmet medical needs in cardiovascular health.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32172,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,69,108,64,498],"class_list":["post-32171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cvd","tag-high-blood-pressure","tag-rnai-aso","tag-rona-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China&#039;s National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32171\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871\" \/>\n<meta property=\"og:description\" content=\"Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China&#039;s National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32171\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T05:54:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-22T05:54:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871\",\"datePublished\":\"2025-04-22T05:54:48+00:00\",\"dateModified\":\"2025-04-22T05:54:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171\"},\"wordCount\":181,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2203.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CVD\",\"High blood pressure\",\"RNAi \\\/ ASO\",\"Rona Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32171#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32171\",\"name\":\"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2203.webp\",\"datePublished\":\"2025-04-22T05:54:48+00:00\",\"dateModified\":\"2025-04-22T05:54:49+00:00\",\"description\":\"Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32171\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32171#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871 - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32171","og_locale":"en_US","og_type":"article","og_title":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871","og_description":"Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.","og_url":"https:\/\/flcube.com\/?p=32171","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-22T05:54:48+00:00","article_modified_time":"2025-04-22T05:54:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32171#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32171"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871","datePublished":"2025-04-22T05:54:48+00:00","dateModified":"2025-04-22T05:54:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32171"},"wordCount":181,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp","keywords":["Clinical trial approval \/ initiation","CVD","High blood pressure","RNAi \/ ASO","Rona Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32171#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32171","url":"https:\/\/flcube.com\/?p=32171","name":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32171#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32171#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp","datePublished":"2025-04-22T05:54:48+00:00","dateModified":"2025-04-22T05:54:49+00:00","description":"Shanghai-based Rona Therapeutics Inc., a developer of siRNA medicines, has announced that it has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) for its RN1871. This siRNA drug targets angiotensinogen (AGT) and is designed to treat hypertension by silencing AGT mRNA expression in the liver.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32171#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32171"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32171#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp","width":1080,"height":608,"caption":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32171#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Rona Therapeutics Wins NMPA IND Approval for siRNA Hypertension Drug RN1871"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32171"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32171\/revisions"}],"predecessor-version":[{"id":32173,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32171\/revisions\/32173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32172"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}